No Data
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
Compass Therapeutics Price Target Announced at $5.00/Share by Ladenburg Thalmann
Compass Therapeutics Analyst Ratings
Ladenburg Thalmann Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Cuts Target Price to $5
Ladenburg Thalmann analyst Aydin Huseynov maintains $Compass Therapeutics(CMPX.US)$ with a buy rating, and adjusts the target price from $9 to $5.According to TipRanks data, the analyst has a
Ladenburg Thalmann Upgrades Compass Therapeutics to Buy From Neutral
Compass Therapeutics to Participate in Upcoming Investor Events
No Data
No Data